Contact this trialFirst, we need to learn more about you.
Aurora kinase inhibitor
Alisertib + Paclitaxel for Breast Cancer
Recruiting1 awardPhase 2
Including Dallas And Austin, Texas
This trial will study alisertib in combination with paclitaxel to find out if the two drugs together can help to control HR-positive, HER2-negative or HR-negative, HER2-negative (triple negative) locally recurrent or metastatic breast cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.